The 10 analysts offering 12-month price forecasts for United Therapeutics Corp have a median target of 191.50, with a high estimate of 255.00 and a low estimate of 102.00. The median estimate represents a +14.54% increase from the last price of 167.19.
The current consensus among 11 polled investment analysts is to Buy stock in United Therapeutics Corp. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $2.95
Reporting Date Mar 03
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.